Thalidomide Treatment of Metastatic Renal-Cell Carcinoma

Publication
Article
OncologyONCOLOGY Vol 14 No 11
Volume 14
Issue 11

Thalidomide (Thalomid) has antiangiogenic and immunomodulatory properties with activity in myeloma and other tumors. We treated 15 patients with advanced progressive metastatic renal-cell cancer with escalating divided daily doses of thalidomide

Thalidomide (Thalomid) has antiangiogenic and immunomodulatory properties with activity in myeloma and other tumors. We treated 15 patients with advanced progressive metastatic renal-cell cancer with escalating divided daily doses of thalidomide beginning at 400 mg/d and increasing 200 mg every 14 days to 1,200 mg/d (50% of each dose was given at bedtime). Nine of 15 patients had a performance status > 1. Currently, 12 patients have received 4+ weeks of therapy and are evaluable for response.

One patient with an initial performance status of 3 has a partial response of 11+ months duration and one patient has a minor response of 3+ months. Three patients have stable disease and seven have progressive disease. Both responders had failed high-dose interleukin-2 therapy. Maximally tolerated doses of thalidomide were 600 to 1,200 mg/d. The usual toxicities of somnolence and constipation were seen, but no cytopenias, neuropathy, or respiratory depression. Some patients developed either arterial or venous thrombi or impaired wound healing, but these events may have been unrelated to thalidomide. Vascular endothelial growth factor levels will be measured in some patients.

CONCLUSION: Thalidomide can produce occasional responses in poor performance status patients with metastatic renal-cell cancer. This study continues to define the maximally tolerated dose in this patient population as well as the response rate.

Click here to read Wen-Jen Hwu's commentary on this abstract.

© 2000 by PRR, Inc. All rights reserved.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content